New York, Feb 6, 2026, 18:48 EST — After-hours
- Boston Scientific wrapped up Friday at $76.27, off 1.8%, following a choppy week for the stock.
- Wednesday’s selloff turned historic, after the company missed in its electrophysiology business and trimmed its 2026 outlook.
- Next week, traders are eyeing early-quarter demand cues as they wait for the next earnings update, which is set for late April.
Boston Scientific Corp finished Friday at $76.27, down 1.8%. The stock barely moved after the bell, still near its post-earnings slump from earlier this week. Roughly 34.9 million shares changed hands.
Why does it matter? Boston Scientific’s valuation has been riding high on rapid gains from just a few key heart businesses. Instead of a moment of triumph, this week forced investors to question their conviction.
Shares of the medical-device maker tumbled as much as 17% on Wednesday—the steepest single-day drop in over 25 years—after quarterly sales in its electrophysiology division, seen by many investors as a key growth driver, landed below forecasts. Citi’s Joanne Wuensch put it bluntly: “their worries were not misplaced.” J.P. Morgan, for its part, flagged that “investors now have reason to question the trajectory” for both the electrophysiology and Watchman units. CEO Mike Mahoney, though, remains upbeat, saying the electrophysiology market could see roughly 15% growth in 2026, with Boston Scientific aiming to beat that pace. Reuters
The stock clawed back 2.83% Thursday, finishing at $77.64. That recovery, though, evaporated by Friday.
Boston Scientific this week reported fourth-quarter net sales of $5.286 billion, with adjusted earnings at $0.80 per share. The company pointed to new regulatory wins and clinical progress in its pulsed field ablation portfolio—specifically, it notched both FDA approval and a CE mark for the FARAPOINT catheter, and began enrollment for the OPTIMIZE clinical trial. CEO Mahoney described 2025 as “another exceptional year” for Boston Scientific. Boston Scientific
Pulsed field ablation, a relatively recent technique for atrial fibrillation, relies on electrical pulses to zero in on heart tissue. The space has turned into a hotly contested arena among medtech players, with even slight shifts in procedure numbers or uptake sending expectations one way or the other in a hurry.
Boston Scientific trailed its rivals even as U.S. stocks rallied. The S&P 500 climbed roughly 2% Friday. Abbott shares advanced, Medtronic barely budged—highlighting that Boston Scientific’s recent slump stands apart.
Monday will give traders a read on whether the electrophysiology dip was just a blip last quarter or points to deeper trouble. U.S. Watchman demand also stays under the microscope after missing forecasts.
Still, there’s a straightforward risk here. Should growth in electrophysiology procedures slow beyond what management is projecting — or if rivals ramp up the pressure — Boston Scientific’s 2026 forecast might not hold up. That could mean the stock’s recent swings stick around.
Investors aren’t waiting for headlines—they’re eyeing the numbers. According to Investing.com’s earnings calendars, the next report comes April 29. That’s the day traders will want to see signs of early-2026 momentum in both electrophysiology and Watchman.
